Creative medical technology holdings receives fda clearance to initiate a phase 1/2 clinical trial of stemspine® using allostem™ (celz-201-ddt) for the treatment of chronic lower back pain

Phoenix , sept. 19, 2023 /prnewswire/ -- creative medical technology holdings, inc. ("creative medical technology" or the "company") (nasdaq: celz), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today announced that the u.s. food and drug administration ("fda") has cleared the company to proceed with a phase 1/2 clinical trial of stemspine® using allostem™ ("celz-201-ddt").
CELZ Ratings Summary
CELZ Quant Ranking